10-Q: Cocrystal Pharma Faces Going Concern Amid Cash Shortfall

Cocrystal Pharma reported significant net losses and declining cash, raising substantial doubt about its ability to continue as a going concern, despite progress in antiviral drug development.

Summary

• Cocrystal Pharma, a clinical-stage biopharmaceutical company, reported a net loss of $4.356 million for the six months ended June 30, 2025, a significant improvement from the $9.299 million loss in the prior year period.
• Cash and restricted cash decreased to $4.841 million as of June 30, 2025, down from $9.935 million at December 31, 2024.
• Net cash used in operating activities was $5.094 million for the six months ended June 30, 2025, compared to $8.202 million for the same period in 2024, primarily due to reduced clinical trial expenses.
• Research and development expenses decreased to $2.482 million for the six months ended June 30, 2025, from $7.258 million in the prior year, mainly due to the progression of the Influenza CC-42344 and Norovirus/Coronavirus CDI-988 candidates through initial high-cost clinical trial phases.
• General and administrative expenses also decreased to $1.967 million for the six months ended June 30, 2025, from $2.348 million in the prior year, attributed to wage reductions and lower legal and other G&A costs.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern, and management believes current resources are insufficient to fund operations beyond the next 12 months.
• The Phase 2a human challenge study for oral CC-42344 (influenza candidate) requires an extension and potential protocol amendment due to an unexpectedly low influenza infection rate among study participants.
• The Phase 1 study for CDI-988 (norovirus/coronavirus candidate) showed favorable safety and tolerability across all tested doses (100 mg to 1,200 mg), with headache being the most common adverse event.
• Stockholders approved a new 2025 Equity Incentive Plan, reserving 1.5 million shares initially, with automatic annual increases of 5% of outstanding common stock for nine years, up to a total of 4 million shares.
• No sales were made under the At-The-Market (ATM) Offering Agreement during the six months ended June 30, 2025, with approximately $7.25 million remaining available under the facility.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the explicit 'going concern' warning, insufficient cash for 12 months of operations, and the necessity for significant dilutive capital raises. While there is some clinical progress, the severe financial instability and trial delays overshadow these positives, indicating a very high-risk investment.

Positives

• Net loss significantly decreased to $4.356 million for the six months ended June 30, 2025, from $9.299 million in the prior year, indicating reduced operational burn.
• Net cash used in operating activities decreased by $3.108 million, reflecting a reduction in clinical trial and employee-related expenses.
• CDI-988 Phase 1 study demonstrated favorable safety and tolerability across all doses (100 mg to 1,200 mg), with no serious adverse events or drug-related discontinuations.
• CDI-988 showed broad-spectrum activity against newly circulating GII.17 norovirus strains and high potency against the H5N1 avian influenza A strain (EC50, 0.003 M).
• CC-42344 Phase 2a study has shown a favorable safety and tolerability profile to date, with no serious adverse events or drug-related discontinuations.
• The company's influenza A/B preclinical development assets were returned from the Merck collaboration, allowing continued internal development.

Negatives

• Cash and restricted cash declined by over 50% from $9.935 million at December 31, 2024, to $4.841 million at June 30, 2025.
• Management believes current cash resources are insufficient to fund operations beyond the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• The Phase 2a study for CC-42344 (influenza) requires an extension and potential protocol amendment due to an unexpectedly low influenza infection rate, indicating a delay in obtaining critical efficacy data.
• The company has historically incurred net losses and negative operating cash flows since inception and has no products approved for sale.
• Future operations are dependent on raising additional capital, which may not be available on acceptable terms or at all, and any equity financing may be very dilutive to existing stockholders.
• The new 2025 Equity Incentive Plan allows for significant future dilution with up to 4 million shares available for grants.

Risks

• Inability to raise additional capital on favorable terms or at all, which could force delays, reductions, or elimination of clinical trials or R&D programs, or even cessation of operations.
• Risks arising from inflation, interest rate increases, the possibility of a recession, and the economic impact of global conflicts on the company, partners, and economies.
• Manufacturing and research delays due to raw materials and labor shortages, supply chain disruptions, and other business interruptions.
• Challenges for Contract Research Organizations (CROs) to recruit volunteers for and proceed with clinical studies.
• Potential adverse findings or delays in the ongoing clinical trials for CC-42344 and CDI-988.
• General risks inherent in clinical trials, including unforeseen complications or failures.
• Failure to receive necessary regulatory approvals or delays in obtaining them.
• Regulatory changes that could adversely impact product development or commercialization.
• Competition from currently available treatments and therapies, as well as from larger pharmaceutical companies developing effective treatments and/or vaccines.
• Potential mutations in targeted viruses that may result in variants resistant to developed product candidates.

Future Outlook

The company expects to continue incurring substantial operating losses and negative cash flows from operations over the next several years during its pre-clinical and clinical development phases. Future cash requirements will depend on factors such as economic conditions, product approval success, R&D progress, clinical trial outcomes, regulatory approvals, intellectual property costs, competitive product status, financing availability, market development success, and legal proceedings. The company intends to fund future operations through additional private or public equity offerings and strategic partnerships, but cannot assure that additional funding will be available on acceptable terms or at all, and any equity financing may be very dilutive.

Management Comments

• We believe that our current resources will not be sufficient to fund our operations beyond the next 12 months.
• The ability to continue as a going concern is dependent upon the ability to raise additional funds and implement strategies.
• If unable to obtain adequate capital, we could be forced to cease operations or substantially curtail drug development activities.
• An extension of the CC-42344 Phase 2a study is necessary due to low infectivity rate of the challenge influenza strain used in this study, as robust influenza infection in healthy, uninfected study subjects is critical to determine clinical endpoints.
• We are currently in continuing discussions with the clinical research organization to address this study and determine a course forward, including potentially preparing a protocol amendment or a resubmission for approval by the MHRA to seek enrollment of additional healthy subjects.

Industry Context

Cocrystal Pharma operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically focusing on antiviral drug development. The company's pipeline addresses significant global health concerns like influenza (including pandemic strains), norovirus (a leading cause of gastroenteritis with no effective treatment or vaccine), and coronavirus (including SARS-CoV-2 variants). The Hepatitis C market is competitive but offers opportunities for ultra-short treatment regimens, which is the company's goal. The ongoing need for novel antivirals is driven by viral mutations, drug resistance, and the emergence of new strains, positioning Cocrystal's broad-spectrum approach as potentially valuable if successful. However, the industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles, making sustained funding a critical challenge.

Comparison to Industry Standards

• The company's goal of developing ultra-short (4-6 weeks) combination oral treatments for Hepatitis C (CC-31244) aims to surpass current market leaders like Harvoni (12 weeks), Viekira Pak (12 weeks), Epclusa (12 weeks), Zepatier (12 weeks), and Mavyret (8 weeks), which currently offer longer treatment durations. No competing company has yet developed a short HCV treatment of less than 8 weeks with a high (>95%) sustained virologic response (SVR) at week 12.
• For norovirus, the company is developing a novel antiviral candidate in a landscape where there is currently no effective treatment or vaccine. Competitors in vaccine development include Vaxart Pharmaceutical, Moderna, Hillevax, Takeda Pharmaceuticals, Anhui Zhifei Longcom Biopharmaceutical (China), and National Vaccine and Serum Institute (China).
• In the influenza space, the company's CC-42344 targets a novel mechanism of action and has shown activity against Tamiflu and Xofluza resistant strains, addressing a key industry challenge of viral resistance to approved treatments like oseltamivir phosphate (Tamiflu), zanamavir (Relenza), and baloxavir marboxil (Xofluza).
• For coronaviruses, the company's CDI-988 aims to be a broad-spectrum antiviral, complementing existing approved treatments like Veklury (remdesivir), Paxlovid (nirmatrelvir/ritonavir), Olumiant (baricitinib), and Actemra (tocilizumab), which primarily target COVID-19.

Corporate Governance

Legal Proceedings

• No material changes to the description of legal proceedings set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, were reported during the period.

Related Party Transactions

• The company has a lease for its Miami, Florida office location with a limited liability company controlled by Dr. Phillip Frost, a director and principal stockholder. This lease was renewed on August 14, 2024, for a 36-month term, with an annualized straight-line rent expense of approximately $64,000. Total rent and other expenses paid in connection with this lease were $32,000 for the six months ended June 30, 2025.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future equity offerings and the newly approved 2025 Equity Incentive Plan. The 'going concern' warning indicates a high risk of capital loss if additional funding is not secured.
• **Employees:** The new equity incentive plan provides a framework for compensation, potentially aiding in retention, but the company's financial instability could create job insecurity if funding is not secured.
• **Customers (potential):** Progress in antiviral drug candidates (CC-42344, CDI-988) offers hope for future treatments for influenza, norovirus, and coronavirus, addressing unmet medical needs.
• **Suppliers/Creditors:** May face increased risk due to the company's 'going concern' status and reliance on future capital raises for liquidity.
• **Regulatory Authorities:** The company's clinical trial progress and adherence to regulatory requirements (e.g., MHRA for CC-42344 study amendment) are critical for product development and approval.

Next Steps

• Continue discussions with the clinical research organization to address the CC-42344 Phase 2a study, including potentially preparing a protocol amendment or a resubmission for approval by the MHRA to seek enrollment of additional healthy subjects.
• Secure additional funding through private or public equity offerings or strategic partnerships to fund ongoing operations and development programs.
• Continue preclinical development activities for the influenza A/B program, which was returned from the Merck collaboration.
• Utilize the 2025 Equity Incentive Plan for future equity awards to employees, directors, and independent contractors.

Key Dates

Recommendation

The company's explicit 'going concern' warning, coupled with a cash balance insufficient to fund operations beyond the next 12 months, presents an immediate and severe financial risk. While there is some clinical progress, the need for substantial dilutive capital raises and the delay in a key Phase 2a trial for CC-42344 significantly undermine investment viability. A seasoned investor would prioritize the fundamental financial instability and the high probability of further dilution, making a 'sell' recommendation prudent to avoid potential significant capital loss.

Keywords

Antiviral drugs, Biopharmaceutical, Clinical stage, Influenza, Norovirus, Coronavirus, Hepatitis C, Drug development, Clinical trials, SEC filing, Going concern, CC-42344, CDI-988, CC-31244